# EDGAR Filing Document

**Accession Number:** 0001805087
**File Stem:** 0000950170-23-000421
**Filing Date:** 2023-1
**Character Count:** 30626
**Document Hash:** 176ba78f2da3a40a5e22b3fdea78e47c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-23-000421.hdr.sgml**: 20230109

**ACCESSION NUMBER**: 0000950170-23-000421

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20230109

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230109

**DATE AS OF CHANGE**: 20230109

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GELESIS HOLDINGS, INC.
- **CENTRAL INDEX KEY:** 0001805087
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 844730610
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39362
- **FILM NUMBER:** 23516480

**BUSINESS ADDRESS:**
- **STREET 1:** 501 BOYLSTON STREET, SUITE 6102
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116
- **BUSINESS PHONE:** 857-327-7737

**MAIL ADDRESS:**
- **STREET 1:** 501 BOYLSTON STREET, SUITE 6102
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CAPSTAR SPECIAL PURPOSE ACQUISITION CORP.
- **DATE OF NAME CHANGE:** 20200227

?xml version="1.0" encoding="ASCII"? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

**FORM** 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** January 09, 2023<br>

------

Gelesis Holdings, Inc.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-39362 | 84-4730610 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| 501 Boylston Street<br>Suite 6102 |  |  |
| Boston**,** Massachusetts |  | 02116 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** 617 456-4718<br>

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **<br>Title of each class** | **Trading<br>Symbol(s)** | **<br>Name of each exchange on which registered** |
| Common stock, par value $0.0001 per share | GLS | New York Stock Exchange |
| Redeemable warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50 | GLS WS | New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 7.01 Regulation FD Disclosure**

On January 9, 2023, the Company updated its corporate presentation for use in meetings with investors, analysts and others. A copy of the corporation presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

The information furnished pursuant to this Item 7.01 and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 9.01 Exhibits.**

**(d) Exhibits.**

---

| | |
|:---|:---|
| **Exhibit**<br>**Number** | **Description** |
| 99.1 | [<u>Gelesis Holdings, Inc. Corporate Presentation - January 9, 2023</u>](gls-ex99_1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | **Gelesis Holdings, Inc.** |
| Date: | January 9, 2023 | By:  | /s/ Elliot Maltz |
|  |  |  | Elliot Maltz <br>**Chief Financial Officer**<br>**(Principal Financial Officer and Accounting Officer)** |

---

------

## Exhibit 99.1

------

### Attached PDF Documents

**Attachment 1:** `gls-ex99_1.pdf`

Ex-99.1

![img-0.jpeg](img-0.jpeg)

GELESIS

# Forward Looking Statements

Certain statements, estimates, targets and projections in this presentation may constitute 'forward-looking statements' within the meaning of the federal securities laws. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'should,' 'strive,' 'would' and similar expressions may identify forward-looking statements, but the absence of these words does not mean that statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Forward-looking statements include, but are not limited to, statements regarding Gelesis' or its management team's expectations, hopes, beliefs, intentions or strategies regarding the future, including those relating to Gelesis' expected operating and financial performance and market opportunities. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Gelesis assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Gelesis gives no assurance that any expectations set forth in this press release will be achieved. Various risks and uncertainties (some of which are beyond Gelesis' control) or other factors could cause actual future results, performance or events to differ materially from those described herein. Some of the factors that may impact future results and performance may include, without limitation: (i) the ability of Gelesis to raise financing, if and when needed; (ii) the ability of Gelesis to continue as a going concern; (iii) Gelesis' ability to achieve and maintain widespread market acceptance of Penity; (iv) the impact of current and future applicable laws and regulations and Gelesis' ability to comply with such laws and regulations; (v) Gelesis' ability to produce adequate supply of Penity, including Gelesis' ability to continue to invest in manufacturing capacity and to build additional manufacturing sites; (vi) the development of the telehealth market and regulations related to remote healthcare; (vii) global economic, political and social conditions and uncertainties in the markets that Gelesis serves, including risks and uncertainties caused by the COVID-19 pandemic or other natural or man-made disasters; (viii) Gelesis' ability to enter into strategic collaborations, to acquire businesses or products or form strategic alliances and to realize the benefits of such collaborations, acquisitions and alliances; (ix) the level of demand, and willingness of potential members to pay out-of-pocket for, Penity; (x) the ability of Gelesis to enforce its intellectual property rights and proprietary technology; (xi) the risk that a third-party's activities, including with respect to third parties that Gelesis has granted out licenses to or granted limited exclusive or non-exclusive commercial rights, may overlap or interfere with the commercialization of Penity; (xii) Gelesis' ability to successfully develop and expand its operations and manufacturing and to effectively manage such growth; (xiii) Gelesis' business partners' ability to successfully launch and commercialize Penity in certain key markets; (xiv) risk relating to the loss of Gelesis' suppliers or distributors, or their inability to provide adequate supply of materials or distribution; (xv) the risk that Gelesis' business partners may experience significant disruptions in their operations; (xvi) Gelesis' ability to retain its senior executive officers and to attract and keep senior management and key scientific and commercial personnel; (xvii) Gelesis' ability to identify and discover additional product candidates and to obtain and maintain regulatory approval for such candidates; (xviii) risks related to potential product liability exposure for Penity or other future product candidates; (xix) risks related to adverse publicity in the weight management industry, changes in the perception of Gelesis' brands, and the impact of negative information or inaccurate information about Gelesis on social media; (xx) Gelesis' ability to enhance its brand recognition, increase distribution of Penity and generate product sales and reduce operating losses going forward; (xxi) the impact of risks associated with economic, financial, political, environmental and social matters and conditions on Gelesis' supply chain, its manufacturing operations and other aspects of its business; (xxii) Gelesis' ability to accurately forecast revenue and appropriately monitor its associated expenses in the future; (xxiii) Gelesis' ability to compete against other weight management and wellness industry participants or other more effective or more favorably perceived weight management methods, including pharmaceuticals, devices and surgical procedures; (xxiv) foreign currency fluctuations and inflation; (xxv) the risk that Gelesis fails to maintain adequate operational and financial resources or to raise additional capital or generate sufficient cash flows; (xxvi) Gelesis' ability to successfully protect against security breaches and other disruptions to its information technology structure; (xxvii) the ability of Gelesis to maintain its listing on the New York Stock Exchange; (xxviii) failure to realize the anticipated benefits of the business combination; and (xxix) other important factors discussed in the 'Risk Factors' section of Gelesis' most recent Annual Report on Form 10-K and in other filings that Gelesis makes with the Securities and Exchange Commission. These filings address other important risks and uncertainties that could cause actual results and events to differ materially from those contained in the forward-looking statements.

This presentation also contains information using industry publications that generally state that the information contained therein has been obtained from sources believed to be reliable, but such information may not be accurate or complete. While we are not aware of any misstatements regarding the information from these industry publications, we have not independently verified any of the data from third-party sources nor have we ascertained the underlying economic assumptions relied on therein.

2

![Gelesis logo]() GELESIS

# Changing the Lives of Millions of People Struggling with Excess Weight

![img-1.jpeg](img-1.jpeg)

☑

Plenity is our FDA-cleared weight management product

☑

Since we launched Plenity Rx, we have helped 185,000 people and generated $36.8M of revenue*

☑

We now plan to multiply our impact with a potential OTC / non-Rx launch

* Cumulative product revenue, net, from Plenity first being made commercially available through September 30, 2022

GELESIS

# Majority of Americans Want to Lose <40 Pounds1
Most of Them Don't Want / Qualify for & Can't Afford Rx Drugs

US Population2

![img-2.jpeg](img-2.jpeg)

Plenty

Label Covers >150M Americans
of which 61million interested in losing 10+ pounds

~$75B3 opportunity in weight loss and weight management

![img-3.jpeg](img-3.jpeg)

Diet & exercise
don't work
for the majority of
people

1. Based on Qualtrics survey assessing consumer weight loss goals for people with a BMI between 25-40

2. Based on 2013-2014 cycle of NHANES data

3. MarketResearch.com: "U.S. Weight Loss Market Shrinks by 25% in 2020 with Pandemic, but Rebounds in 2021" by John LaRosa, on March 10, 2022

4

GELESIS

# To Impact Millions Who are Waiting, the Ideal Weight Loss Product Should Be

![img-4.jpeg](img-4.jpeg)

1. Safe & Easy

![img-5.jpeg](img-5.jpeg)

2. Effective & Proven

![img-6.jpeg](img-6.jpeg)

3. Affordable & Accessible

To date, other weight loss products or services have fallen short

![img-7.jpeg](img-7.jpeg)

5

![GELESIS logo]() GELESIS

# Meet Plenity: FDA Cleared, Clinically Proven & Well Tolerated
Designed to make you Feel Fuller, Eat Less, and Lose Weight

![img-8.jpeg](img-8.jpeg)

## 1. Safety & Ease

**Safety:**
Unprecedented safety profile as demonstrated in our clinical trials and our real-world data

**Ease:** Three pills, twice daily

![img-9.jpeg](img-9.jpeg)

## 2. Effective & Proven

**Effectiveness:** 6 out of 10 people in our FDA clinical trials lost an average of 22 lbs and 3.5 inches in only 24 weeks

**Proven:** Strong sales growth with high consumer satisfaction

![img-10.jpeg](img-10.jpeg)

## 3. Affordable & Accessible

**Affordable:** Costs $1.75 per dose and can be purchased easily online

**Accessible:** With broad online distribution **without an Rx** (coming soon1)

![img-11.jpeg](img-11.jpeg)

1. Pending FDA approval

6

GELESIS

# Safety & Ease

Plenity Breakthrough Technology is the Only Superabsorbent Hydrogel Made Entirely from Naturally Derived Building Blocks

![img-12.jpeg](img-12.jpeg)

![img-13.jpeg](img-13.jpeg)

![img-14.jpeg](img-14.jpeg)

![img-15.jpeg](img-15.jpeg)

Within minutes, the capsules dissolve and form a large volume of small non-aggregating gel pieces, with composition & firmness similar to ingested raw vegetables

Plenity creates a similar effect to eating 1⁄2 pound of cucumber before meals, simply by taking a few capsules

7

![GELESIS logo]()

# Safety & Ease: Feel Fuller Throughout the Day with Less Food

Not Absorbed, Not Habit Forming, Induces Satiety and Weight Loss by Increasing the Volume and Firmness of the Ingested Meals without any Additional Calories

![img-16.jpeg](img-16.jpeg)

Capsules taken
with water
before a meal

![img-17.jpeg](img-17.jpeg)

Create small
gel pieces that
fill ~1/4 of
the stomach

![img-18.jpeg](img-18.jpeg)

Gel pieces
mixed with the
meal increase its
volume & reduce
its caloric
density1

![img-19.jpeg](img-19.jpeg)

Increasing the
volume and
firmness of food
also in the
small intestine

![img-20.jpeg](img-20.jpeg)

Not absorbed &
eliminated through
the natural
digestive process

1

2

3

4

5

1. The number of calories in a given mass of food

Source: Rolls, B. J. The relationship between dietary energy density and energy intake. Physiol. Behav. 97, 609-615.

8

GELESIS

# Effective & Proven

## Robust Efficacy and Safety in Clinical Trials and the Real World

### Responders

Adults **achieving 5% or greater** weight loss
in only 24 weeks

![img-21.jpeg](img-21.jpeg)

These responders lost on average 10% of their
weight (22 lbs) and ~3.5 inches from their waist

Plenity doubled the odds of achieving 5%
or greater weight loss compared with placebo

### Super Responders

Adults **achieving 10% or greater** weight loss
in only 24 weeks

![img-22.jpeg](img-22.jpeg)

were “super-responders” to
Plenity, **losing on average
14% of their weight (30 lbs)**

### Safety / Side Effects / Tolerability

Plenity had a side effect profile equal to placebo,
and no serious adverse events

9

Source: Greenway, F. et. al. A Randomized, Double-Blind, Placebo-Controlled Study of Gelesis100: A Novel Nonsystemic Oral Hydrogel for Weight Loss. *Obesity*(2018)

GELESIS

# Effective & Proven

## Strong Sales Growth from Consumer Awareness Marketing

### What We Have Proven

#### Ability to obtain customers

185k new customers since launch

#### Product message resonates in market

175% YoY revenue growth shows immediate and robust response to media campaign in 1H-22

#### Ability to improve margins

35% higher gross margin after commercial manufacturing investments and packaging improvements

#### Product performance

Unprecedented safety profile mirror clinical results; demonstrated improved retention metrics

### Quarterly Revenues and Gross Margin

![img-23.jpeg](img-23.jpeg)

10

![GELESIS logo]()

# Effective & Proven
...with High Consumer Satisfaction

Plenity weight loss support

Hey all, it's been awhile.

In total I've lost 82 pounds and I'm almost to 15% body fat which was my ultimate goal. I've started going to the gym and got a personal trainer in the past month, but I waited because I wanted to lose significant amount of fat better... See more

It didn't happen overnight but 13 months later we are just 19 pounds away from pre-baby weight. Plenity really helped kick off my weight loss journey and continues to help me from overeating and encourages me to get my proper water intake everyday.
Starting weight 195lbs
Current weight 154lbs
Goal weight 135lbs

I've lost 82 pounds and I'm almost to 15% body fat which was my ultimate goal. I've started going to the gym and got a personal trainer in the past month, but I waited because I wanted to lose significant amount of fat better... See more

It didn't happen overnight but 13 months later we are just 19 pounds away from pre-baby weight. Plenity really helped kick off my weight loss journey and continues to help me from overeating and encourages me to get my proper water intake everyday.
Starting weight 195lbs
Current weight 154lbs
Goal weight 135lbs

I've lost 82 pounds and I'm almost to 15% body fat which was my ultimate goal. I've started going to the gym and got a personal trainer in the past month, but I waited because I wanted to lose significant amount of fat better... See more

It's a good time to get my proper water intake everyday.

Starting weight 195lbs
Current weight 154lbs
Goal weight 135lbs

I've lost 82 pounds and I'm almost to 15% body fat which was my ultimate goal. I've started going to the gym and got a personal trainer in the past month, but I waited because I wanted to lose significant amount of fat better... See more

It's a good time to get my proper water intake everyday.

Starting weight 195lbs
Current weight 154lbs
Goal weight 135lbs

I've lost 82 pounds and I'm almost to 15% body fat which was my ultimate goal. I've started going to the gym and got a personal trainer in the past month, but I waited because I wanted to lose significant amount of fat better... See more

It's a good time to get my proper water intake everyday.

Starting weight 195lbs
Current weight 154lbs
Goal weight 135lbs

5 days ago

## A new lease on losing weight

I'm 59 years old and have had weight problems for the last 25 years. I began Plenity 2 months ago I've lost over 20lbs and have not had the feeling of hunger at all. I have felt better, eaten better and moved my body more than ever. Thank you Plenity

Date of experience: November 09, 2022

## Really Works

This product did exactly what it proposed. I was doing another diet program, but I found that I was always hungry and not exercising like I wanted to do. This product took away that hungry feeling, I ate less, and I had more energy.

Date of experience: October 19, 2022

Oct 20, 2022

Check out our 117 reviews

Trustpilot

11

GELESIS

# Affordable & Accessible
## Plenity OTC Advantages over Rx

![img-0.jpeg](img-0.jpeg)

2X Larger Addressable Market

26M targeted population for Rx vs. 65M for OTC1

Anticipated Significant Reduction in CAC

Single digit purchase rate2 as Rx vs 30% for e-commerce benchmark (anticipated)3

New, Broader Distribution Partner Opportunities

Limited to only Rx channels vs. multiple as OTC, such as online retailers (e.g. Amazon) and brick & mortar, as well as broader partnership opportunities

Lower Commercial Infrastructure Costs & HCP Marketing Telehealth Costs

Eliminating Gelesis healthcare provider sales force costs and saving consumer cost of physician visit

12

1. Based on potential utilization of Plenity earlier in weight loss journey prior to spending money in category
2. Consumer who started an online visit then purchased Plenity
3. This value is an average calculated based on 41 different studies containing statistics on e-commerce shopping cart abandonment . (source: Baymard Institute)

GELESIS

# Plenity OTC: Why Now?

Accumulated safety record with >185,000 people. Unprecedented real-world safety and tolerability consistent with the clinical studies

Customers want easy access: ~98% drop off from Rx website$^{1}$. Many also prefer the privacy and control of their weight loss journey

Growing interest in category with new products not addressing majority of Americans

**Michael 'Mike' Albert, MD**

Plenity is currently available only by Rx, but I believe it has the ability to be a billion dollar product as an OTC wt loss aid. There is nothing that compares in safety & efficacy available OTC. At the right price pt, it's a multi-billion $ product (think PPIs as a comparable).

10:24 PM · 6/21/22 · Twitter for iPhone

**Submission 1Q23 with anticipated approval of OTC middle of 2023**

1. Percentage of people who visit website who ultimately don't purchase product via myplenity.com

13

![GELESIS logo]() GELESIS

# OTC Makes the Purchase Process Simpler and Easier
## Only 3 Steps Without Need for Medical Data or Photos...

Rx steps required by consumer:

20+ min process

1 Starts online visit

2 Begins questionnaire

3 Uploads photo

4 Provides ID

5 Provides credit card info

6 Dr follow-up with clarifying questions

7 Dr assesses fit for product

8 Credit is charged and
Plenity sent to member

Low Percentage Purchase Rate for Online Visit

OTC steps required by consumer:

~1 min process

1 Clicks "buy Plenity"

2 Adds product to cart

3 Provides credit card info
& Plenity sent to member

Anticipated 30% Purchase Rate
Based on Benchmarks1

Could Improve Purchase Process Efficiency up to 3-5X

14

1. This value is an average calculated based on 41 different studies containing statistics on e-commerce shopping cart abandonment . (source: Baymard Institute)

GELESIS

# >2X Larger Target Population

OTC target consumer starts earlier on in the weight loss journey

Rx Plenity Target Audience

![img-1.jpeg](img-1.jpeg)

OTC Plenity Target Audience

![img-2.jpeg](img-2.jpeg)

Benchmark Data

- 15% of US adults have taken weight loss supplements1
- 30% of weight loss supplement purchased are online1
- Which means there are approximately 30M adults buying weight loss supplements and approximately 10M buying them online

15

1. Grand View Research Industry Analysis

GELESIS

# New Distribution Opportunities as OTC Drive Broader Access
## Current Distribution Limited to Telehealth & Traditional Prescribing

### E-commerce

- Myplenity.com
- Telehealth (non-Rx)
- Large online retailers: e.g. Amazon

![img-3.jpeg](img-3.jpeg)

### Partnerships / Non-traditional

- **Healthcare Professionals:** Physicians, registered dietitians
- **Health and Wellness Outlets:** e.g. Equinox, Lifetime, Barry's Bootcamp, Medspas
- **Weight Management Companies:** e.g. Jenny Craig, Nutrisystem, Noom

![img-4.jpeg](img-4.jpeg)

### Brick & Mortar

- Retail pharmacies
- Major Retailers: e.g., Target & Walmart, GNC, Vitamin Shoppe

![img-5.jpeg](img-5.jpeg)

16

GELESIS

# Strategic Focus Over Next 12 Months

By Switching to OTC, Gelesis Aims to Make Plenity a Blockbuster Over Time

**Access:** Transformational change in go-to-market strategy driving efficient growth

- Remove Rx hurdle to lower barriers to usage
- Partner with top e-commerce platforms and wellness companies for OTC distribution / expand network
- Turn myplenity.com into a DTC commerce site

**Profitability:** Improve margins while driving towards profitability within 2 years of OTC launch

- Keep consumer pricing affordable
- Remove costs of Rx & improve CAC by increasing conversion
- Further improve COGS and packaging efficiencies

**Reach:** Continue to expand global footprint in other geographies

- Starting in Asia, followed by other key markets with geographic partnerships as a source of additional non-dilutive funding and increase revenues

**Near-term Milestones**1

**Q1 2023:** Submit to FDA for OTC status

**Q3 2023:** Anticipated FDA approval of OTC status

**Q4 2023:** Launch Plenity OTC / Non-Rx

17

1. Anticipated milestones are subject to timing of FDA review and other factors beyond Company's control.

GELESIS

# Team with Deep Entrepreneurial, Operational & Industry Experience

Key Hires in 2023: CBO & Commercial OTC Lead

![img-6.jpeg](img-6.jpeg)

Yishai Zohar

CEO & Founder

- Entrepreneur & co-inventor with strong track record of launching industry, innovating companies & delivering results in a capital efficient way.
- Built Gelesis from inception through FDA clearance w/ minimal spend. Led all aspects of science, clinical, manufacturing & operations
- Co-founded PureTech (Nasdaq: PRTC), a biopharma company developing ground-breaking therapeutics

![img-7.jpeg](img-7.jpeg)

David Pass

Chief Commercial Officer

- 25+ years of commercial & BD expertise across therapeutic areas with a focus on consumer driven markets
- Built and led diabetes franchise in Alliance between Eli Lilly and Boehringer-Ingelheim

![img-8.jpeg](img-8.jpeg)

Elaine Chiquette

Chief Scientific Officer

- 15+ years of leadership experience in pharmaceutical, biotechnology, and medical device industry
- Most recently served as VP of Medical Affairs at GI Dynamics

![img-9.jpeg](img-9.jpeg)

Elliot Maltz

Chief Financial Officer

- 15+ years of accounting and corporate finance experience working with public and private companies
- Previously held leadership roles at Deloitte & Touche LLP and Sapient Corp.

![img-10.jpeg](img-10.jpeg)

Joy Bauer, MS, RDN, CDN

Chief Nutrition Officer of Plenity

- Well-known TV and media personality and a #1 New York Times bestselling author with 14 bestsellers to her credit
- Director of Nutrition and Fitness for the Department of Pediatric Cardiology at Mount Sinai Medical Center in New York City, as well as the clinical dietitian for their neurosurgical team

![img-11.jpeg](img-11.jpeg)

Alessandro Sannino

Ph.D., Head of Material Science & Inventor

- Co-inventor of the GS100 technology, Professor of Polymer Science & Technology and the director of the Biolabs at University of Salento
- Oversees Life Science division of the Puglia District of Technology and adjunct faculty at Massachusetts Institute of Technology (MIT)

Living proof.

18

GELESIS

# Backed by Top Clinical and Consumer Advisors

Clinical Advisors

![img-12.jpeg](img-12.jpeg)

Louis J. Aronne,
M.D., FACP

Scientific Advisor

- Sanford I. Weill
Professor of Metabolic
Research at Weill-
Cornell Medical
College where he
directs the
Comprehensive
Weight Control Center
- Associate Professor of
Clinical Medicine
appointment at
Columbia University

![img-13.jpeg](img-13.jpeg)

Ken Fujioka,
M.D.

Scientific Advisor

- Director of the
Nutrition Metabolic
Research Center
at Scripps College
- Authored over 100
papers in peer-
reviewed journals
(including NEJM,
The Lancet, JAMA,
DOM, and
Obesity) on weight
management,
and related
comorbid diseases

![img-14.jpeg](img-14.jpeg)

James Hill,
Ph.D.

Scientific Advisor

- Professor of
Medicine &
Pediatrics,
University of
Colorado
- Past President of
The Obesity
Society (TOS)
- Director of the
Colorado Nutrition
Obesity
Research Center.

Consumer Advisors

![img-15.jpeg](img-15.jpeg)

Elon Boms

Investor & Advisor

- Co-founded
LaunchCapital,
portfolio
performance
since 2010 has
recorded IRR that
has placed
LaunchCapital in
the top 10% of
venture funds
worldwide.
- History of working
with industry
disruptors like
Arccos Golf,
Gelesis, Adimab,
Pico Trading,
Snap, Spotify,
and more

![img-16.jpeg](img-16.jpeg)

Jane Wildman

Board Member

- 25 years at Procter
& Gamble, working
in beauty, health,
baby, feminine
care, and food
- Global Vice
President for
Pampers, P&G's
largest brand
- Corporate
strategy, omni-
channel marketing,
transforming the
user experience,
and multi-cultural
marketing for
clients like,
including Walmart,
P&G, and Nestle

![img-17.jpeg](img-17.jpeg)

Clayton
Christopher

Board Member

- Founder and former
CEO of Sweetleaf
Tea, Deep Eddy
Vodka & Waterloo
Sparkling Water
- Co-founder of CAVU
Venture Partners
- Awarded the Ernst &
Young Entrepreneur
of the year Austin
Under 40 Austinite
of the Year

![img-18.jpeg](img-18.jpeg)

Kathryn
Cavanaugh

Board Member

- Early investor in
leading direct to
consumer brands,
including Rothy's
and ThirdLove
- Advisor to
Parachute Home,
Primary Kids,
Supergoop!,
MM.Lafleur, and
Sarah Flint
- Partner at Grace
Beauty Capital

19

GELESIS

# Investment Highlights for Large Upside Opportunity

## 1. Safety & Ease

**Safety:** Unprecedented safety profile as demonstrated in our clinical trials and our real-world data

**Easy:** 3 pills, twice daily

## 2. Effective & Proven

**Effectiveness:** 6 out of 10 people in our FDA clinical trials lost an average of 22 lbs and 3.5 inches in only 24 weeks

**Proven:** Strong sales growth with high consumer satisfaction

## 3. Affordable & Accessible

**Affordable:** Costs $1.75 per dose and can be purchased easily online

**Accessible:** Next, expand access to millions who are waiting

![img-19.jpeg](img-19.jpeg)

Transformational technology addressing one of the world's largest and relapsing health problems

20

![GELESIS logo]() GELESIS